Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor –T-cell therapy in B-cell non-Hodgkin lymphomas-Reference-Cited by-同舟云学术

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor –T-cell therapy in B-cell non-Hodgkin lymphomas

Published:2018-12 Issue:12 Volume:20 Page:1415-1418
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Shah Nirav N.^ORCID,Nagle Sarah J.,Torigian Drew A.,Farwell Michael D.,Hwang Wei-Ting,Frey Noelle,Nasta Sunita D.,Landsburg Daniel,Mato Anthony,June Carl H.,Schuster Stephen J.,Porter David L.,Svoboda Jakub

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics(clinical),Oncology,Immunology,Immunology and Allergy

Reference8 articles.

1. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification;Cheson;J Clin Oncol,2014

2. FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?;Zijlstra;Haematologica,2016

3. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma;Ulaner;J Clin Oncol,2014

4. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas;Schuster;N Engl J Med,2017

5. Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods;Malek;Blood Cancer Journal,2015

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume;Blood;2024-06-13

2. FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL);Nuklearmedizin - NuclearMedicine;2024-04-09

3. Role of FDG PET/CT in Patients With Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy: Current Concepts;American Journal of Roentgenology;2024-03

4. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy;Cancer Medicine;2024-03

5. Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy;Journal for ImmunoTherapy of Cancer;2023-10